Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis
International Journal of Molecular Sciences · 27.09.2023 · 24 (19) · 14611
DOI: 10.3390/ijms241914611 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.09.2023. Verfasst von Meera Vyas und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Neuroscience Studies, Queen's University, Kingston, ON K7L 3N6, Canada. Hauptthemen laut MEDLINE: Tay-Sachs Disease, Gangliosidoses, GM2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Queen's University, Queen’s University.
Abstract (Originalsprache)
GM2 gangliosidoses are a group of neurodegenerative lysosomal storage disorders that are characterized by the accumulation of GM2 gangliosides (GM2), leading to rapid neurological decline and death. The hydrolysis of GM2 requires the specific synthesis, processing, and combination of products of three genes—HEXA, HEXB, and GM2A—within the cell’s lysosomes. Mutations in these genes result in Tay-Sachs disease, Sandhoff disease, or AB-variant GM2 gangliosidosis (ABGM2), respectively. ABGM2, the rarest of the three types, is characterized by a mutation in the GM2A gene, which encodes the GM2 activator (GM2A) protein. Being a monogenic disease, gene therapy is a plausible and likely effective method of treatment for ABGM2. This study aimed at assessing the effects of administering a one-time intravenous treatment of single-stranded Adeno-associated virus serotype 9 (ssAAV9)-GM2A viral vector at a dose of 1 × 1014 vector genomes (vg) per kilogram per mouse in an ABGM2 mouse model (Gm2a−/−). ssAAV9-GM2A was administered at 1-day (neonatal) or 6-weeks of age (adult-stage). The results demonstrated that, in comparison to Gm2a−/− mice that received a vehicle injection, the treated mice had reduced GM2 accumulation within the central nervous system and had long-term persistence of vector genomes in the brain and liver. This proof-of-concept study is a step forward towards the development of a clinically therapeutic approach for the treatment of patients with ABGM2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Neuroscience Studies, Queen's University, Kingston, ON K7L 3N6, Canada.
- Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada.
- Department of Pediatrics, Queen's University, Kingston, ON K7L 2V7, Canada.
- Department of Pediatrics, UT Southwestern Medical Center, Dallas, TX 75390, USA.
ORCID-Profile: Natalie M Deschenes, Steven J Gray
Förderung
- Queen's University
- Queen’s University
Zitieren
APA
Vyas, M., Deschenes, N. M., Osmon, K. J. L., Chen, Z., Ahmad, I., Kot, S., Thompson, P., Richmond, C., Gray, S. J., & Walia, J. S. (2023). Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis. International Journal of Molecular Sciences, 24(19), 14611. https://doi.org/10.3390/ijms241914611
Vancouver
Vyas M, Deschenes NM, Osmon KJL, Chen Z, Ahmad I, Kot S, et al. Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis. International Journal of Molecular Sciences. 2023;24(19):14611. doi:10.3390/ijms241914611
BibTeX
@article{Vyas2023,
author = {Vyas, Meera and Deschenes, Natalie M and Osmon, Karlaina J L and Chen, Zhilin and Ahmad, Imtiaz and Kot, Shalini and Thompson, Patrick and Richmond, Chris and Gray, Steven J and Walia, Jagdeep S},
title = {Efficacy of Adeno-Associated Virus Serotype 9-Mediated Gene Therapy for AB-Variant GM2 Gangliosidosis},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {19},
pages = {14611},
doi = {10.3390/ijms241914611}
}
EUVIMED